NASDAQ$MDXG
Mimedx Group Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
MiMedx Group, Inc. announced its operating and financial results for the fourth quarter and full year 2024, reporting solid growth in net sales and Adjusted EBITDA margin.
MiMedx Group, Inc. reported strong fourth quarter and full year 2024 results, with net sales growing 7% year-over-year for the quarter to $93 million and Adjusted EBITDA margin at 21% of net sales. The company also generated strong free cash flow, despite challenges in Medicare reimbursement.
- Net sales for Q4 2024 increased by 7% year-over-year to $93 million.
- Adjusted EBITDA for Q4 2024 was $20 million, representing 21% of net sales.
- Gross profit for Q4 2024 was $76 million, an increase of $3 million compared to the prior year period.
- The company maintained a strong cash position, with $104 million in cash and cash equivalents as of December 31, 2024.
Headline financials
Revenue & EPS history
Mimedx · Revenue · Quarterly
$92.9M
Forward guidance
Provided that future effective LCDs go into effect as currently planned, MIMEDX expects net sales growth of at least high single-digits as a percentage and Adjusted EBITDA margin above 20% for the full-year 2025. Longer-term, the Company continues to expect to achieve annual net sales growth in the low double-digits as a percentage with an Adjusted EBITDA margin above 20%.
Tailwinds
- Expected net sales growth of at least high single-digits for FY 2025.
- Anticipated Adjusted EBITDA margin above 20% for FY 2025.
- Longer-term annual net sales growth expected in the low double-digits.
- Continued focus on developing innovative products for Wound and Surgical businesses.
- Strengthening relationships with customers.
Headwinds
- Future effective LCDs (Local Coverage Determinations) are a condition for the guidance.
- Potential for significant disruption from ongoing manipulation of the Medicare reimbursement system in the private office.
- Uncertainty regarding future sales due to competition and patient access to healthcare providers.
- Risks associated with the reimbursement environment.
- Potential for changes in market conditions requiring rapid adjustments.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.7%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+7.2%
Avg return
30 days after
53%
34 / 64 earnings
Positive
+37.9%
Q1 2023
Best reaction
-23.3%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.1% | +6.2% | +8.2% | |
| Q4 2025 | -0.9% | -8.8% | -28.8% | |
| Q3 2025 | +2.6% | +7.0% | -4.3% | |
| Q1 2025 | -8.1% | -3.9% | -6.5% | |
| Q4 2024 | +1.6% | +1.1% | -5.9% | |
| Q3 2024 | +17.9% | +22.7% | +59.2% | |
| Q2 2024 | -12.0% | -17.7% | -9.9% | |
| Q1 2024 | +16.8% | +17.7% | +13.7% | |
| Q4 2023 | -2.9% | -1.7% | -8.3% | |
| Q3 2023 | +6.7% | +10.9% | +26.5% | |
| Q2 2023 | -4.6% | -4.2% | -8.1% | |
| Q1 2023 | +37.9% | +49.1% | +50.4% | |
| Q4 2022 | -11.4% | -6.4% | -29.0% | |
| Q3 2022 | -3.6% | +1.3% | +12.6% | |
| Q2 2022 | +8.2% | +15.5% | +2.3% | |
| Q1 2022 | +11.1% | -8.9% | -4.8% | |
| Q4 2021 | +1.4% | -1.6% | -4.0% | |
| Q3 2021 | +18.8% | +22.6% | +2.5% | |
| Q2 2021 | -2.5% | +1.4% | +23.4% | |
| Q1 2021 | -2.9% | -5.0% | +2.0% | |
| Q4 2020 | -15.3% | -13.4% | +13.8% | |
| Q3 2020 | +3.4% | -8.2% | -5.6% | |
| Q2 2020 | +2.3% | +4.2% | +14.4% | |
| Q2 2018 | +8.2% | +3.2% | +18.2% | |
| Q1 2020 | +8.2% | +3.2% | +18.2% | |
| Q4 2018 | +8.2% | +3.2% | +18.2% | |
| Q4 2019 | +8.2% | +3.2% | +18.2% | |
| Q2 2019 | +8.2% | +3.2% | +18.2% | |
| Q1 2018 | +8.2% | +3.2% | +18.2% | |
| Q1 2019 | +8.2% | +3.2% | +18.2% | |
| Q3 2019 | +8.2% | +3.2% | +18.2% | |
| Q4 2017 | -21.6% | -22.1% | -14.0% | |
| Q3 2018 | -1.3% | -8.6% | -7.0% | |
| Q3 2017 | +4.1% | +8.7% | -4.9% | |
| Q2 2017 | +0.7% | +2.1% | +5.9% | |
| Q1 2017 | +8.2% | +19.1% | +17.5% | |
| Q4 2016 | -3.9% | +3.4% | +9.8% | |
| Q3 2016 | +4.9% | +8.0% | +19.1% | |
| Q2 2016 | -0.9% | -1.7% | -5.6% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -0.4% | — | — | |
| Q3 2015 | -23.3% | — | — | |
| Q2 2015 | -13.5% | — | — | |
| Q1 2015 | +0.9% | — | — | |
| Q4 2014 | +8.7% | — | — | |
| Q3 2014 | +13.2% | — | — | |
| Q2 2014 | +5.5% | — | — | |
| Q1 2014 | -3.8% | — | — | |
| Q4 2013 | +2.2% | — | — | |
| Q3 2013 | -3.5% | — | — | |
| Q2 2013 | +0.8% | — | — | |
| Q1 2013 | -2.2% | — | — | |
| Q4 2012 | +8.5% | — | — | |
| Q3 2012 | +13.5% | — | — | |
| Q2 2012 | -4.8% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | -4.2% | — | — | |
| Q2 2011 | -2.5% | — | — | |
| Q1 2011 | -3.7% | — | — | |
| Q4 2010 | +5.8% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | -4.8% | — | — | |
| Q1 2010 | +4.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro